Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequential Therapy Clear all
Completed Phase 1Phase 2 Interventional

Study of DF1001 in Patients With Advanced Solid Tumors

NCT04143711
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 30, 2026, 1:47 PM EDT
Completed No phase listed Observational

Digital Capillary Refill for Monitoring of Sepsis

NCT04529655
View directory record Official record
Conditions
Sepsis
Interventions
Capillary Refill Assessment
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

NCT01290471
View directory record Official record
Conditions
Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
Interventions
U3-1565
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

NCT02239900
View directory record Official record
Conditions
Liver Cancer, Lung Cancer
Interventions
Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 30, 2026, 1:47 PM EDT
Active, not recruiting Phase 3 Interventional

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01349972
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride, cytarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 30, 2026, 1:47 PM EDT
Terminated Phase 3 Interventional

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00002772
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, carmustine, cisplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 30, 2026, 1:47 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Transcranial Magnetic Stimulation for Chronic Scrotal Content Pain

NCT07035119
View directory record Official record
Conditions
Scrotal Pain
Interventions
Transcranial magnetic stimulation
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Tranexamic Acid in Reverse Total Shoulder Arthroplasty

NCT02043132
View directory record Official record
Conditions
Shoulder Joint Disease, Complications; Arthroplasty, Intraoperative Complications, Blood Loss, Surgical
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 30, 2026, 1:47 PM EDT
Terminated Phase 2 Interventional Results available

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

NCT02663271
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
Interventions
Bevacizumab, Optune, Brain MRI, Quality of Life Questionnaires
Drug · Device · Other
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

NCT02555306
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Neuromodulation Therapy Device for the Treatment of Sleep Apnea

NCT01117064
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Neuromodulation Therapy Device (NMTD)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 30, 2026, 1:47 PM EDT
Recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864
View directory record Official record
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
volrustomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott Valley, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 1:47 PM EDT
Terminated Not applicable Interventional Results available

Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphedema

NCT01239160
View directory record Official record
Conditions
Lymphedema
Interventions
Flexitouch System, Hydroven FPR
Device
Lead sponsor
Tactile Medical
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Phoenix, Arizona • Chicago, Illinois • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

NCT03249103
View directory record Official record
Conditions
Fibromyalgia
Interventions
NYX-2925, Placebo oral capsule
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bausch Health Thermage FXL for Use on Lower Face and Submentum Area

NCT04606368
View directory record Official record
Conditions
Skin Wrinkling
Interventions
Thermage FLX
Device
Lead sponsor
Lorraine Hickson
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 30, 2026, 1:47 PM EDT
Terminated Phase 1 Interventional Results available

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

NCT04296942
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
Interventions
Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 30, 2026, 1:47 PM EDT
Active, not recruiting Phase 3 Interventional

Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection

NCT04241341
View directory record Official record
Conditions
Breast Cancer Lymphedema
Interventions
Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction, Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction, quality-of-life questionnaires, measured by arm volume
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

NCT00005779
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12, HIV-1 C4-V3 Polyvalent Peptide Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 30, 2026, 1:47 PM EDT
Withdrawn Phase 1 Interventional

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

NCT05634954
View directory record Official record
Conditions
Breast Cancer
Interventions
GEH121224 (18F) Injection, Dynamic and Static - PET/CT Scan, Static - PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NCT03636256
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
Interventions
NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Drug · Other
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 30, 2026, 1:47 PM EDT
Completed Not applicable Interventional Results available

Brief Cognitive Behavioral Therapy for Military Populations

NCT02038075
View directory record Official record
Conditions
Suicide, Suicidal Ideation
Interventions
Brief Cognitive Behavioral Therapy (BCBT), Treatment As Usual (TAU)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 30, 2026, 1:47 PM EDT